Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Am J Clin Oncol. 2011 Apr;34(2):179-87. doi: 10.1097/COC.0b013e3181d6b427.

Melanoma: from darkness to promise.

Author information

  • 1Medical Oncology Service, Hospital Marina Alta de Dénia, Alacant, Spain. joanmagasent@telefonica.net

Abstract

Metastatic melanoma is one of the most resistant tumors to standard chemotherapy approaches. The median overall survival of patients diagnosed with metastatic melanoma is lower than 9 months. Current approved treatments offer only marginal survival advantages. New immunotherapeutic targets have appeared recently trying to modulate the host immune response against the tumor. New targeted agents have changed the standard of care of other solid tumor types like breast cancer. Here, we discuss the new advances and achievements in the treatment of this highly resistant disease.

PMID:
20498590
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk